Clinical trial 2y update | Avelumab first-line maintenance for advanced urothelial carcinoma

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up – Journal of Clinical Oncology

Original Article: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma – New England Journal of Medicine